Lung Cancer Clinical Trials 2026: Targeted Therapy, Immunotherapy & Early Detection

Twenty years ago, a metastatic NSCLC diagnosis meant cytotoxic chemotherapy and a median survival measured in months. The molecular revolution changed that — osimertinib for EGFR-mutant disease, lorlatinib for ALK, sotorasib and adagrasib for KRAS G12C, and pembrolizumab for high PD-L1 expressors have collectively transformed a disease once treated uniformly into molecularly defined subtypes with substantially different prognoses. The 2026 research agenda reflects what those victories also revealed: resistance is inevitable, and roughly a third of patients still lack an actionable driver mutation and don't respond durably to immunotherapy. Those are the hard problems driving the current trial pipeline.

Molecular Subtypes: Why Biomarkers Determine Your Trial Options

NSCLC is classified primarily by molecular driver — adenocarcinoma vs. squamous matters less than EGFR vs. KRAS vs. ALK vs. none. The trial landscape for each subtype is completely distinct:

• EGFR mutations (15–20% of NSCLC): Osimertinib is standard first-line. FLAURA2 showed adding chemotherapy extends median PFS from 16.7 to 25.5 months — meaningful but at the cost of added toxicity, so it's now a calibrated decision for individual patients. Fourth-generation EGFR inhibitors targeting C797S (the resistance mutation that emerges after osimertinib) are in Phase 1/2, including BLU-945 and BBT-176. Combination trials testing fourth-gen + osimertinib upfront are exploring whether you can preempt resistance rather than treat it when it appears.
• KRAS G12C (13% of NSCLC): Sotorasib and adagrasib achieve ORRs of 37–43% in second line, but resistance develops in months via feedback reactivation of RAS pathway signaling. Next-generation KRAS inhibitors — olomorasib and glecirasib — use different binding approaches and are in Phase 2/3. The most rational strategy may be upfront combination: KRAS G12C inhibitor plus SHP2 inhibitor to block the feedback loop, or plus PD-1 inhibitor to combine target therapy with immune activation.
• ALK rearrangements (5%): Lorlatinib is standard first-line after CROWN trial showed 60.2% PFS at 3 years vs. 32.5% for crizotinib. CNS metastases remain the main problem — occurring in 40–50% of patients over time — and current trials focus on combination strategies and next-generation agents for specific lorlatinib-resistance mutations.
• RET, MET exon 14, ROS1, NTRK, BRAF V600E, HER2: All have approved targeted therapies with active trials developing next-generation drugs or extending approved agents to earlier disease stages. Each is a separate research track requiring specific molecular confirmation at enrollment.

Immunotherapy in 2026: Breaking Through the Response Ceiling

For patients without actionable driver mutations, pembrolizumab is standard first-line for PD-L1 ≥50% (ORR ~45%), and chemo-pembrolizumab combinations are used for PD-L1 <50%. The central problem: roughly 50–60% of patients don't achieve durable responses, and there's no reliable predictive biomarker beyond PD-L1 and TMB.

• TIGIT inhibitors: Domvanalimab, tiragolumab, and vibostolimab in Phase 3 combinations with PD-1 inhibitors. Early Phase 2 signals were encouraging, but several Phase 3 trials have returned neutral results. The class hasn't definitively failed — patient selection criteria are being refined for new trials.
• Perioperative immunotherapy (KEYNOTE-671): Pembrolizumab given neoadjuvantly before surgery and adjuvantly after in resectable Stage II–IIIA NSCLC produced 62.4% 24-month EFS vs. 40.6% for chemotherapy alone — a landmark result that's reshaping early-stage treatment. The perioperative design has become the template for multiple ongoing trials.
• Bispecific antibodies: Several bispecific T-cell engagers and bispecific checkpoint inhibitors are in Phase 1/2, targeting PD-1 plus a second checkpoint (LAG-3, TIGIT, TIM-3) in a single molecule. The hypothesis is simultaneous dual blockade produces more sustained T-cell activation than sequential therapy.
• Consolidation after chemoradiation: Durvalumab (PACIFIC) established the standard in Stage III unresectable disease. The LAURA trial showed osimertinib consolidation after chemoradiation in EGFR-mutant Stage III NSCLC produced PFS of 39.1 months vs. 5.6 for placebo — a striking result in this molecularly defined subset.

Small Cell Lung Cancer: Tarlatamab and the T-Cell Engager Era

SCLC is biologically distinct from NSCLC — aggressive, initially chemo-sensitive but rapidly relapsing, without actionable molecular drivers in the traditional sense. For decades, second-line options were essentially topotecan and lurbinectedin — drugs that work briefly in a minority of patients.

Tarlatamab (Imdelltra) changed the equation. This DLL3×CD3 bispecific T-cell engager recruits cytotoxic T cells to DLL3-expressing tumor cells. DLL3 is expressed on 80–85% of SCLC cells and negligibly on normal adult tissues — making it a reasonably tumor-selective target. The DeLLphi-301 trial showed an ORR of 40% and median OS of 14.3 months in patients with at least two prior lines of therapy. FDA accelerated approval followed in May 2024. Phase 3 DeLLphi-304 is testing tarlatamab as first-line maintenance after platinum-based chemotherapy — if positive, it could fundamentally change first-line SCLC care.

Molecular Profiling: What You Need Before Searching for Trials

For lung cancer trial eligibility, comprehensive molecular profiling is non-negotiable — it determines which trials you qualify for. A full workup includes: broad NGS panel (EGFR including exon 20 insertions, KRAS G12C and G12D, ALK, ROS1, RET, MET exon 14 skip, BRAF V600E, NTRK1/2/3, HER2 exon 20); PD-L1 by IHC (22C3 assay); TMB; and liquid biopsy/ctDNA for monitoring and resistance mutation detection when tissue rebiopsy isn't feasible.

Patients with prior tissue biopsy may have an outdated molecular profile — tumors evolve under treatment pressure, and resistance mechanisms driving progression often involve new mutations not present at diagnosis. Many trials require a fresh biopsy within 3–6 months of enrollment. The Lung Cancer Foundation of America's LCFA trial matching service can help translate a complex molecular report into specific trial matches.